Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Grant and collaboration revenue	$ 415,458	$ 333,209	$ 1,572,037	$ 907,382
Operating expenses:
Research and development	416,756	467,674	1,687,113	1,474,619
General and administrative	435,013	291,475	1,364,650	1,214,189
Total operating expenses	851,769	759,149	3,051,763	2,688,808
Loss from operations	(436,311)	(425,940)	(1,479,726)	(1,781,426)
Other income (expense):
Interest income	90	2,560	902	4,665
Interest expense	(134,427)	(1,054)	(142,722)	(3,275)
Total other income (expense)	(134,337)	1,506	(141,820)	1,390
Net loss	$ (570,648)	$ (424,434)	$ (1,621,546)	$ (1,780,036)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (0.73)	$ (1,282.28)	$ (2.85)	$ (14,016.03)
Weighted average shares outstanding (in shares)	782,978	331	569,955	127